US · Healthcare · Biotechnology
EPS came in at -0.98 against a street estimate of -1.03 — a beat of 4.9%.
Analysts rate Avalyn Pharma Inc. Common Stock a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $61.80.
| Fund | Stake |
|---|---|
| FMR Inc | 13.16% |
| Novo A/S | 8.76% |
| SR ONE CAPITAL MANAGEMENT, LP | 7.46% |
| Perceptive Advisors LLC | 6.03% |
| Suvretta Capital Management, LLC | 5.65% |
| NVP Associates LLC | 5.12% |
| Wellington Management Company LLP | 4.97% |
| T. Rowe Price Associates, Inc. | 3.91% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 AVALYN PHARMA INC. - 8-K FILING SUMMARY HEADLINE NUMBERS • New board director appointment effective September 15, 2026 • Director compensation: $40, | 2026-09-16 |
| Quarterly report · Q2 2026 AVALYN PHARMA INC. — 10-Q SUMMARY (Q2 2026) --- HEADLINE NUMBERS • Cash position: $264.2 million (June 30, 2026) vs. $52.3 million (December 31, 20 | 2026-08-12 |
| Results announced · Q3 2026 AVALYN PHARMA INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash position: $413.5 million in cash, cash equivalents, and marketable securities | 2026-08-12 |
| Material agreement · Q2 2026 AVALYN PHARMA INC. – 8-K SUMMARY HEADLINE NUMBERS • Company expanded its Boston office space by 4,934 rentable square feet (56% increase) • Premises | 2026-07-01 |
| Reg FD disclosure · Q2 2026 AVALYN PHARMA INC. (AVLN) - 8-K SUMMARY HEADLINE NUMBERS • Company: Avalyn Pharma Inc., Delaware-incorporated, trading on Nasdaq Global Select Marke | 2026-06-17 |
| Quarterly report · Q1 2026 AVALYN PHARMA INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $92.3 million in cash and cash equivalents as of March 31, 2026 (up from | 2026-06-03 |
| Results announced · Q2 2026 AVALYN PHARMA INC. – Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position (Pre-IPO): $123.1 million in cash, cash equivalents, and marketable | 2026-06-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Avalyn Pharma Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.